Evolution and design of metamorphic fold-switching proteins
变态折叠转换蛋白的进化和设计
基本信息
- 批准号:10733814
- 负责人:
- 金额:$ 62.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-16 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdoptedAffinityAnimalsBindingBiologicalBiological ModelsBiomedical TechnologyBreathingCategoriesCell surfaceChemicalsChemotaxisComputing MethodologiesDendritic CellsEngineeringEquilibriumEvolutionExtracellular MatrixFamilyG-Protein-Coupled ReceptorsGlycosaminoglycansGoalsHealthHumanImmune systemKnowledgeLeukocyte TraffickingLocomotionMachine LearningMapsMeasuresMethodsMolecular ConformationMutationNMR SpectroscopyNanotechnologyNaturePhysicsPhysiologicalProteinsRecording of previous eventsRoleStructureStructure-Activity RelationshipTestingThermodynamicsXCL1 geneXCR1 geneantimicrobialbeta pleated sheetbiophysical propertieschemokinechemokine receptordesigndimerdisulfide bondexperimental studyflexibilityimprovedmonomernoveloptical sensorpressureprotein foldingreceptorreceptor bindingreconstructionthermostabilitytool
项目摘要
Project Summary/Abstract
The goals of this project are to understand how and why a metamorphic protein evolved from a non-
metamorphic ancestor and develop a method for de novo design of fold-switching proteins. Nearly all
known proteins adopt a single folded structure, but XCL1 is a rare example of a fold-switching, or
metamorphic, protein. Metamorphic proteins reversibly exchange between two entirely different,
incompatible structures. Experiments proposed in specific aim 1 seek to answer the question: why is
human XCL1 metamorphic? We hypothesize that fold-switching conferred a functional advantage to an
XCL1 ancestor that was subsequently optimized for its role in the human immune system. XCL1 binds
and activates the chemokine receptor XCR1 using the conserved chemokine fold. However, we
discovered that an atypical receptor binds the non-chemokine fold, and may have exerted selective
pressure on XCL1 evolution. We will define the structural basis for XCL1 recognition by both receptors.
We recently used ancestral sequence reconstruction to show that XCL1 evolved from a non-
metamorphic chemokine fold and identified the sequence changes that permitted spontaneous
interconversion with an unrelated beta sheet structure. Specific aim 2 will define structure-function
relationships for the resurrected XCL1 ancestors and test the hypothesis that cold denaturation of the
beta sheet structure enables interconversion with the chemokine fold. In specific aim 3, we will use
Rosetta and AlphaFold2 to identify novel sequences that shift between two distinct, folded, monomeric
helical bundle structures. Structural dynamics of the most promising designs will be characterized by
NMR and other biophysical measurements. Metamorphic designs and related monomorphic sequences
will be systematically analyzed to assess the relative importance of interface optimization, flexibility or
strain, and internal contact networks and identify features required to encode multiple structures in a
single protein. Collectively, the proposed studies will provide a deeper understanding of the
evolutionary origin and design of fold-switching proteins, an important but underrepresented category of
biomolecules.
项目概要/摘要
该项目的目标是了解变态蛋白如何以及为何从非变态蛋白进化而来。
变态祖先并开发了一种从头设计折叠转换蛋白的方法。几乎所有
已知的蛋白质采用单折叠结构,但 XCL1 是折叠转换的罕见例子,或者
变质, 蛋白质.变质蛋白在两种完全不同的、
不相容的结构。具体目标 1 中提出的实验试图回答这个问题:为什么
人类XCL1变质?我们假设折叠转换赋予了功能优势
XCL1 祖先随后针对其在人类免疫系统中的作用进行了优化。 XCL1 结合
并使用保守的趋化因子折叠激活趋化因子受体 XCR1。然而,我们
发现非典型受体结合非趋化因子折叠,并可能发挥选择性
XCL1进化的压力。我们将定义两种受体识别 XCL1 的结构基础。
我们最近使用祖先序列重建来表明 XCL1 是从非
变质趋化因子折叠并确定了允许自发的序列变化
与不相关的β折叠结构的相互转化。具体目标 2 将定义结构-功能
复活的 XCL1 祖先的关系并检验冷变性的假设
β片层结构能够与趋化因子折叠相互转化。在具体目标 3 中,我们将使用
Rosetta 和 AlphaFold2 识别在两个不同的折叠单体之间转换的新序列
螺旋束结构。最有前途的设计的结构动力学特点是
核磁共振和其他生物物理测量。变质设计和相关的单态序列
将进行系统分析,以评估界面优化、灵活性或
应变和内部接触网络,并识别编码多个结构所需的特征
单一蛋白质。总的来说,拟议的研究将提供对
折叠转换蛋白的进化起源和设计,一个重要但代表性不足的类别
生物分子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian F Volkman其他文献
Brian F Volkman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian F Volkman', 18)}}的其他基金
Evolution of fold-switching in the metamorphic chemokine XCL1
变质趋化因子 XCL1 中折叠转换的进化
- 批准号:
10475442 - 财政年份:2021
- 资助金额:
$ 62.64万 - 项目类别:
Targeting CCL28 as therapy for obstructive lung disease
靶向 CCL28 治疗阻塞性肺病
- 批准号:
9282770 - 财政年份:2015
- 资助金额:
$ 62.64万 - 项目类别:
Structural and energetic origins of metamorphic protein folding
变质蛋白质折叠的结构和能量起源
- 批准号:
8735210 - 财政年份:2013
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8084410 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8324405 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8447040 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8639582 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Conformational duality in the human chemokine Ltn/XCL1
人类趋化因子 Ltn/XCL1 的构象二元性
- 批准号:
8301087 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8312146 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors
磺基酪氨酸引导的小分子趋化因子抑制剂的发现
- 批准号:
8245006 - 财政年份:2011
- 资助金额:
$ 62.64万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 62.64万 - 项目类别:
Continuing Grant














{{item.name}}会员




